Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of guselkumab in active psoriatic arthritis after inadequate response to TNF-alpha inhibitors
MOH_2019-03-17_006028Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab with Placebo (2 arms). Primary endpoint: ACR20 response at week 24. Started Mar 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on MOH_2019-03-17_006028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-17_006028.